Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Multicenter Experience with Imatinib Mesylate in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients.

A.M. Carella, MD, E. Lerma, MD, E. Orlandi, MD, M. Lazzarino, MD, M. Annunziata, MD, F. Ferrara, MD, E. Pungolino, MD, E. Morra, MD, M. Miglino, MD, M. Gobbi, MD

Blood (2007) 110 (11): 4554.

https://doi.org/10.1182/blood.V110.11.4554.4554

Published: 2007

Journal Articles

Interferon-alpha (IFN-a) Given Alone to CML Patients with Undetectable Disease after Imatinib (IM) Is Able To Maintain Their Complete Molecular Remission after IM Discontinuation.

A.M. Carella, MD

Blood (2007) 110 (11): 4555.

https://doi.org/10.1182/blood.V110.11.4555.4555

Published: 2007

Journal Articles

Reduced-Intensity Conditioning for Allografting Following Autografting for Myeloma: Lower Relapse Rates Compared with Single or Double Autografting but Similar Overall Survival. The Genoa Experience in 74 Patients.

A.M. Carella, MD, G. Catania, MD, S. Biasco, MD, M. Congiu, MD, S. Nati, MD, E. Rossi, MD, R. Vimercati, MD, D. Ciapanna, MD, M. Spriano, MD

Blood (2007) 110 (11): 5095.

https://doi.org/10.1182/blood.V110.11.5095.5095

Published: 2007

Journal Articles

Disease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies.

Blood (2007) 110 (11): 4930.

https://doi.org/10.1182/blood.V110.11.4930.4930

Published: 2007

Journal Articles

Reduced Intensity Conditioning Regimen for Allografting Following Autografting Has Strong Anti-Myeloma Activity and Delays Disease Progression Compared to Tandem Autografting.

A.M. Carella, MD, E. Lerma, MD, Phd, S. Nati, MD, A. Congiu, MD, E. Rossi, MD, M. Spriano, MD, R. Vimercati, MD

Blood (2006) 108 (11): 51.

https://doi.org/10.1182/blood.V108.11.51.51

Published: 2006

Journal Articles

Therapy-Related Myelodysplastic Syndrome (sMDS) /Acute Myelogenous Leukemia (sAML) in Acute Promyelocytic Leukemia (APL) Patients with Long-Lasting Molecular Remission: The GIMEMA Experience.

R. Latagliata, MD, M. Breccia, MD, P. Fazi, MD, S. Gubbiotti, MD, E. Di Bona, MD, G. Specchia, PhD, A. Chiarenza, MD, R. Murru, MD, A.M. Carella, PhD, F. Ferrara, PhD, G. Rossi, MD, L. Melillo, MD, S. Sica, MD, R. Invernizzi, MD, G. Cimino, PhD, M.C. Petti, PhD, G. Avvisati, PhD, F. Lo-Coco, PhD, F. Mandelli, PhD

Blood (2005) 106 (11): 884.

https://doi.org/10.1182/blood.V106.11.884.884

Published: 2005

Journal Articles

Autografting Followed Closely by Nonmyeloablative Allografting as Consolidation Immunotherapy Reduces Disease Progression Compared to Tandem Autografting in Multiple Myeloma.

A.M. Carella, MD, M. Spriano, MD, M. T. Corsetti, MD, P. Scalzulli, MD, G. Beltrami, MD, E. Lerma, MD, PhD, N. Cascavilla, MD, M. Carella, MD, S. Nati, MD, A. Congiu, MD, P. Musto, MD

Blood (2005) 106 (11): 1126.

https://doi.org/10.1182/blood.V106.11.1126.1126

Published: 2005

Journal Articles

Successful Peripheral Blood Stem Cell (PBSC) Mobilisation with G-CSF in Patients with Chronic Myeloid Leukaemia Achieving Complete Cytogenetic Remission with Imatinib.

A.M. Carella, MD, Maria T. Corsetti, MD, Carlo Bodenizza, MD, Francesco Iuliano, MD, Giulia Pucci, MD, Pasquale Jacopino, MD, Bruno Martino, MD, Maura Brugiatelli, MD, Felicetto Ferrara, MD

Blood (2004) 104 (11): 4652.

https://doi.org/10.1182/blood.V104.11.4652.4652

Published: 2004

Journal Articles

Imatinib Achieves High Rates of Complete Citogenetic Remission (CCR) in CML Patients Relapsed after Autografting anf IFN-α Therapy.

Maria T. Corsetti, MD, Germana Beltrami, MD, A.M. Carella, MD

Blood (2004) 104 (11): 4656.

https://doi.org/10.1182/blood.V104.11.4656.4656

Published: 2004

Journal Articles

Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Metastatic Breast Cancer.

A.M. Carella, MD, Germana Beltrami, MD, Maria T. Corsetti, MD, Potito Scalzulli, MD, Michele Carella, MD, Roberta Gonella, MD, Alberto Ballestreo, MD, Franco Patrone, MD

Blood (2004) 104 (11): 5129.

https://doi.org/10.1182/blood.V104.11.5129.5129

Published: 2004

Journal Articles

Reduced Intensity Conditioning Regimen for Allografting Following Autografting Is Feasible and Has a Strong Anti Multiple Myeloma Activity.

A.M. Carella, MD, Germana Beltrami, MD, Maria T. Corsetti, MD, Potito Scalzulli, MD, Nicola Cascavilla, MD, Michele Carella, MD, Sandro Nati, MD, Mario M. Greco, MD, Pellegrino Musto, MD

Blood (2004) 104 (11): 5130.

https://doi.org/10.1182/blood.V104.11.5130.5130

Published: 2004

Journal Articles

Long-Term Follow-Up of CML Patients Treated with Autografting Followed by IFN-A and Imatinib for Relapsed Patients.

A.M. Carella, MD, Maria T. Corsetti, MD, Germana Beltrami, MD, Carlo Bodenizza, MD, Marina Cavaliere, MD

Blood (2004) 104 (11): 5217.

https://doi.org/10.1182/blood.V104.11.5217.5217

Published: 2004

Journal Articles

Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Relapsed/Resistant Hodgkin’s Lymphoma.

Michele Carella, MD, Germana Beltrami, MD, Maria T. Corsetti, MD, Mario M. Greco, MD, Potito Scalzulli, MD, Nicola Cascavilla, MD, Pellegrino Musto, MD, Antonio La Sala, MD, Matteo Dell’Olio, MD, A.M. Carella, MD

Blood (2004) 104 (11): 5135.

https://doi.org/10.1182/blood.V104.11.5135.5135

Published: 2004

NARROW

Multicenter Experience with Imatinib Mesylate in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients.

Interferon-alpha (IFN-a) Given Alone to CML Patients with Undetectable Disease after Imatinib (IM) Is Able To Maintain Their Complete Molecular Remission after IM Discontinuation.

Reduced-Intensity Conditioning for Allografting Following Autografting for Myeloma: Lower Relapse Rates Compared with Single or Double Autografting but Similar Overall Survival. The Genoa Experience in 74 Patients.

Disease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies.

Reduced Intensity Conditioning Regimen for Allografting Following Autografting Has Strong Anti-Myeloma Activity and Delays Disease Progression Compared to Tandem Autografting.

Therapy-Related Myelodysplastic Syndrome (sMDS) /Acute Myelogenous Leukemia (sAML) in Acute Promyelocytic Leukemia (APL) Patients with Long-Lasting Molecular Remission: The GIMEMA Experience.

Autografting Followed Closely by Nonmyeloablative Allografting as Consolidation Immunotherapy Reduces Disease Progression Compared to Tandem Autografting in Multiple Myeloma.

Successful Peripheral Blood Stem Cell (PBSC) Mobilisation with G-CSF in Patients with Chronic Myeloid Leukaemia Achieving Complete Cytogenetic Remission with Imatinib.

Imatinib Achieves High Rates of Complete Citogenetic Remission (CCR) in CML Patients Relapsed after Autografting anf IFN-α Therapy.

Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Metastatic Breast Cancer.

Reduced Intensity Conditioning Regimen for Allografting Following Autografting Is Feasible and Has a Strong Anti Multiple Myeloma Activity.

Long-Term Follow-Up of CML Patients Treated with Autografting Followed by IFN-A and Imatinib for Relapsed Patients.

Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Relapsed/Resistant Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only